Mike R. Russell

发表

Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma

Andrew C. Wood, Daniel Martinez, Sharon J. Diskin, 2013, Clinical Cancer Research.

RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma

Cynthia Winter, Sharon J Diskin, John M Maris, 2011, Proceedings of the National Academy of Sciences.

The functional variant rs34330 of CDKN1B is associated with risk of neuroblastoma

K. Cole, P. Raman, L. McDaniel, 2017, Journal of cellular and molecular medicine.

CASC15-S Is a Tumor Suppressor lncRNA at the 6p22 Neuroblastoma Susceptibility Locus.

K. Cole, J. Khan, Jun S. Wei, 2015, Cancer research.

Rare variants in TP53 and susceptibility to neuroblastoma.

H. Hakonarson, M. Devoto, J. Maris, 2014, Journal of the National Cancer Institute.

Molecular and Cellular Pathobiology Interleukin-1 b Promotes Skeletal Colonization and Progression of Metastatic Prostate Cancer Cells with Neuroendocrine Features

A. Fatatis, Qingxin Liu, F. Garcia, 2013 .

Microenvironment Factors Influencing Skeletal Metastases

A. Fatatis, Mike R. Russell, D. Jernigan, 2010 .

Combination therapy targeting the Chk1 and Wee1 kinases shows therapeutic efficacy in neuroblastoma.

K. Cole, J. Maris, S. Shumway, 2013, Cancer research.

Tumor and Stem Cell Biology Cancer Research The α-Receptor for Platelet-Derived Growth Factor Confers Bone-Metastatic Potential to Prostate Cancer Cells by Ligand-and Dimerization-Independent Mechanisms

A. Kazlauskas, A. Fatatis, Qingxin Liu, 2010 .

Targeting the α Receptor for Platelet-Derived Growth Factor as a Primary or Combination Therapy in a Preclinical Model of Prostate Cancer Skeletal Metastasis

A. Fatatis, M. Russell, Qingxin Liu, 2010, Clinical Cancer Research.

COMBINATION THERAPY TARGETING THE CHK1 AND WEE1 KINASES DEMONSTRATES THERAPEUTIC EFFICACY IN NEUROBLASTOMA

J. Maris, S. Shumway, M. Russell, 2012 .

The α-receptor for platelet-derived growth factor as a target for antibody-mediated inhibition of skeletal metastases from prostate cancer cells

N. Dolloff, A. Fatatis, Mike R. Russell, 2009, Oncogene.

Human Bone Marrow Activates the Akt Pathway in Metastatic Prostate Cells through Transactivation of the α-Platelet–Derived Growth Factor Receptor

N. Dolloff, A. Fatatis, Mike R. Russell, 2007 .

Preclinical Therapeutic Synergy of MEK1/2 and CDK4/6 Inhibition in Neuroblastoma

K. Cole, G. Caponigro, P. Raman, 2016, Clinical Cancer Research.

Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma

K. Cole, G. Caponigro, J. Maris, 2013, Clinical Cancer Research.

The alpha-receptor for platelet-derived growth factor confers bone-metastatic potential to prostate cancer cells by ligand- and dimerization-independent mechanisms.

A. Kazlauskas, A. Fatatis, Hetian Lei, 2010, Cancer research.

The α -Receptor for Platelet-Derived Growth Factor Confers Bone-Metastatic Potential to Prostate Cancer Cells by Ligand- and Dimerization-Independent Mechanisms

A. Kazlauskas, A. Fatatis, Hetian Lei, 2010 .

Cancer Therapy : Preclinical Dual CDK 4 / CDK 6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma

K. Cole, G. Caponigro, J. Maris, 2013 .